The Application of Immunotherapy in Thyroid Cancer Research
DOI:
https://doi.org/10.53469/wjimt.2025.08(03).01Keywords:
Thyroid cancer, Immunotherapy, Biomarkers, Mechanisms of drug resistanceAbstract
Thyroid cancer is the most common endocrine malignancy globally, with differentiated thyroid cancer (DTC) accounting for 90% of cases. However, advanced and anaplastic thyroid cancer (ATC) still lack effective treatment options. In recent years, immunotherapy has demonstrated potential in refractory thyroid cancer by activating anti-tumor immune responses. This article reviews the clinical progress of strategies such as immune checkpoint inhibitors (ICIs), adoptive cell therapy (ACT), and tumor vaccines, and discusses their biomarkers and mechanisms of drug resistance.
References
Kim, S., Iyer, R., Goswami, S., & Roman, S. A. (2018). Prognostic implications of tumor-infiltrating lymphocytes in differentiated thyroid cancer. Thyroid, 28(1), 33-40.
Landa, I., Ibrahim, Y. H., Toubaji, A., Abou-Alfa, G. K., Busaidy, N. L., Sherman, S. I., & Correa, R. J. (2021). Immune landscape of anaplastic thyroid cancer: The role of tumor-associated macrophages and regulatory T cells. Cancer Cell, 39(2), 237-255.
Zwaenepoel, K., Van den Eynden, G. G., Van den Broeck, A., Rottey, S., Van Laere, S., Pauwels, P., & De Paepe, A. (2020). PD-L1 expression in thyroid cancer: Insights into differential expression and potential for therapeutic targeting. Cancer Immunology, Immunotherapy, 69(11), 2335-2344.
Ahn, S., Kim, H. J., Song, S. Y., Moon, H. J., Jung, K. W., Kang, D., & Kim, T. Y. (2019). Association between PD-L1 expression and BRAF V600E mutation in papillary thyroid cancer. Cancer Research and Treatment, 51(4), 1504-1513.
Mehnert, J. M., Adams, S., Prieto, P. A., Grothey, A., Kalinsky, K., O'Day, S. J., & Le Tourneau, C. (2019). Efficacy and safety of pembrolizumab in advanced thyroid cancer: Results from the phase Ib KEYNOTE-028 study. Thyroid, 29(5), 639-647.
Wirth, L. J., Sherman, E. J., Dadu, R., Busaidy, N. L., Worden, F., Koshkin, V., & Cabanillas, M. E. (2022). Atezolizumab and cobimetinib in patients with locally advanced or metastatic anaplastic thyroid cancer: Results from a phase 1b trial. Lancet Oncology, 23(2), 236-246.
Romano, E., Vinci, V., De Luca, A., Manno, M., Spitaleri, G., Zizzari, I. G., & Corvò, R. (2020). Ipilimumab in combination with stereotactic body radiation therapy for the treatment of advanced thyroid cancer patients: A phase I/II study. Thyroid, 30(1), 86-94.
Li, Z., Liu, Y., Zhang, Y., Zhang, W., Wang, Y., Wu, L.,& Zhang, W. (2021). TSHR-directed CAR T cells eliminate thyroid cancer cells in vitro and in vivo. Cell Reports, 36(13), 109624.
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y. C., Dudley, M. E., & Rosenberg, S. A. (2022). Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science, 372(6549), eabg9376.
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., & Dranoff, G. (2020). An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 578(7795), 294-299.
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V. A., & Hellmann, M. D. (2021). Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Molecular Cancer Therapeutics, 20(5), 1023-1032.
Prete, A., Puglisi, F., De Carlo, E., Colonna, M., & Vitale, G. (2022). RET/PTC rearrangements in thyroid cancer: Implications for MHC class I expression and immunogenicity. Cancer Letters, 510, 23-31.
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin - Ordinas, H., Rodriguez, G. A., & Hugo, W. (2020). Interferon-γ signaling and PD-L1 upregulation enhance immunogenicity and responsiveness to immune checkpoint blockade. Cell Reports, 31(10), 107818.
Cunha, L. L., Zlotoff, D. A., Postow, M. A., & Wolchok, J. D. (2022). Mechanisms of resistance to immune checkpoint inhibitors in cancer therapy. Nature Reviews Cancer, 22(3), 151-164.
Ferrari, S. M., Bertoni, F.,& Del Vecchio, M. (2021). HDAC inhibitors in combination with immune checkpoint inhibitors: A novel approach in cancer immunotherapy. Journal for ImmunoTherapy of Cancer, 9(1), e002078.